CA2722766A1 - Methods for producing enucleated erythroid cells derived from pluripotent stem cells - Google Patents

Methods for producing enucleated erythroid cells derived from pluripotent stem cells Download PDF

Info

Publication number
CA2722766A1
CA2722766A1 CA2722766A CA2722766A CA2722766A1 CA 2722766 A1 CA2722766 A1 CA 2722766A1 CA 2722766 A CA2722766 A CA 2722766A CA 2722766 A CA2722766 A CA 2722766A CA 2722766 A1 CA2722766 A1 CA 2722766A1
Authority
CA
Canada
Prior art keywords
cells
cell
pluripotent stem
human
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2722766A
Other languages
English (en)
French (fr)
Inventor
Robert Lanza
Shi-Jiang Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Institute for Regenerative Medicine
Original Assignee
Advanced Cell Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Cell Technology Inc filed Critical Advanced Cell Technology Inc
Priority to CA3150872A priority Critical patent/CA3150872A1/en
Publication of CA2722766A1 publication Critical patent/CA2722766A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/78—Cellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2722766A 2008-05-06 2009-05-06 Methods for producing enucleated erythroid cells derived from pluripotent stem cells Abandoned CA2722766A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3150872A CA3150872A1 (en) 2008-05-06 2009-05-06 Methods for producing enucleated erythroid cells derived from pluripotent stem cells

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12680308P 2008-05-06 2008-05-06
US61/126,803 2008-05-06
US18949108P 2008-08-19 2008-08-19
US61/189,491 2008-08-19
US19028208P 2008-08-26 2008-08-26
US61/190,282 2008-08-26
PCT/US2009/043050 WO2009137629A2 (en) 2008-05-06 2009-05-06 Methods for producing enucleated erythroid cells derived from pluripotent stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3150872A Division CA3150872A1 (en) 2008-05-06 2009-05-06 Methods for producing enucleated erythroid cells derived from pluripotent stem cells

Publications (1)

Publication Number Publication Date
CA2722766A1 true CA2722766A1 (en) 2009-11-12

Family

ID=41265390

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2722766A Abandoned CA2722766A1 (en) 2008-05-06 2009-05-06 Methods for producing enucleated erythroid cells derived from pluripotent stem cells
CA3150872A Pending CA3150872A1 (en) 2008-05-06 2009-05-06 Methods for producing enucleated erythroid cells derived from pluripotent stem cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3150872A Pending CA3150872A1 (en) 2008-05-06 2009-05-06 Methods for producing enucleated erythroid cells derived from pluripotent stem cells

Country Status (10)

Country Link
US (4) US20110086424A1 (enExample)
EP (2) EP3282010A1 (enExample)
JP (4) JP5748654B2 (enExample)
KR (4) KR101803562B1 (enExample)
CN (3) CN102083960B (enExample)
AU (1) AU2009244236B2 (enExample)
BR (1) BRPI0912517A2 (enExample)
CA (2) CA2722766A1 (enExample)
MX (1) MX2010012089A (enExample)
WO (1) WO2009137629A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102230288B1 (ko) 2006-04-14 2021-03-22 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
WO2009137629A2 (en) 2008-05-06 2009-11-12 Advanced Cell Technology, Inc. Methods for producing enucleated erythroid cells derived from pluripotent stem cells
CN102083963A (zh) 2008-05-06 2011-06-01 先进细胞技术公司 血管瘤集落形成细胞和非移植血管瘤细胞
ES2820873T3 (es) 2008-05-16 2021-04-22 Taiga Biotechnologies Inc Anticuerpos y su procesos de preparación
ES2681478T3 (es) 2008-08-28 2018-09-13 Taiga Biotechnologies, Inc. Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC
US8703487B2 (en) 2009-12-01 2014-04-22 The Regents Of The University Of California Compositions and methods for making and using bone marrow mesenchymal stem cells and erythroid progenitor cells
CA3095576A1 (en) * 2009-12-04 2011-06-09 Astellas Institute For Regenerative Medicine Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
CA2782013C (en) * 2009-12-04 2021-06-08 Stem Cell & Regenerative Medicine International, Inc. Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions
WO2011101468A1 (en) * 2010-02-22 2011-08-25 Université Pierre Et Marie Curie (Paris 6) Cell culture medium for the growth and differentiation of cells of the hematopoietic lineage
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
HRP20181515T1 (hr) * 2011-11-30 2018-11-16 Astellas Institute For Regenerative Medicine Mezenhimne stromalne stanice i upotreba povezana s njima
GB201200458D0 (en) * 2012-01-11 2012-02-22 Nhs Blood & Transplant Methods of preparing cells and compositions
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
WO2014011407A2 (en) 2012-07-12 2014-01-16 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
KR20140011912A (ko) 2012-07-20 2014-01-29 도꾸리쯔교세이호징 리가가쿠 겐큐소 인간 적혈구 전구세포주 및 인간 탈핵 적혈구의 제조방법
GB201212960D0 (en) * 2012-07-20 2012-09-05 Common Services Agency Erythroid production
US9664671B2 (en) 2012-07-24 2017-05-30 Nissan Chemical Industries, Ltd. Culture medium composition and method of culturing cell or tissue using thereof
US10017805B2 (en) 2012-08-23 2018-07-10 Nissan Chemical Industries, Ltd. Enhancing ingredients for protein production from various cells
CN114558032B (zh) 2012-12-21 2025-07-29 安斯泰来再生医药协会 由多能干细胞制备血小板的方法及其组合物
US10272115B2 (en) * 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
PT2970912T (pt) * 2013-03-13 2019-05-31 Wisconsin Alumni Res Found Métodos e materiais para a diferenciação hematoendotelial de células estaminais pluripotentes humanas em condições definidas
WO2014171486A1 (ja) 2013-04-17 2014-10-23 日産化学工業株式会社 培地組成物及び当該培地組成物を用いた赤血球の製造方法
EP2997135B1 (en) * 2013-05-15 2020-04-29 University Of Rochester Human extensively self-renewing erythroblasts (esre)
WO2015032340A1 (en) 2013-09-06 2015-03-12 Shanghai Sidansai Biotechnology Co., Ltd Modified cells for production of blood cells
CN103740642A (zh) * 2014-01-28 2014-04-23 娄彩玲 一种生产人红细胞的方法
CN104694471A (zh) * 2015-03-25 2015-06-10 奥思达干细胞有限公司 体外诱导胚胎干细胞分化为红系细胞的方法
CA2977525A1 (en) * 2015-03-30 2016-10-06 Jeffrey Thomas Loh Methods for producing modified red blood cell compositions, compositions and uses thereof
US11319528B2 (en) 2015-07-13 2022-05-03 University Of Utah Research Foundation Methods of making red blood cells and platelets in vitro and uses thereof
TW202417023A (zh) 2015-08-18 2024-05-01 美商安斯泰來再生醫藥協會 臨床調配物
WO2017123312A2 (en) 2015-09-02 2017-07-20 Regeneration Worldwide Company, Inc. Composition and methods of using umbilical cord lining stem cells
WO2017059477A1 (en) 2015-10-07 2017-04-13 Sangui Bio Pty. Ltd Blood preparation and profiling
US11564948B2 (en) 2015-12-22 2023-01-31 Sangui Bio Pty Ltd Therapeutic methods using erythrocytes
CN106834224A (zh) * 2016-11-18 2017-06-13 西北农林科技大学 一种建立人多能干细胞诱导分化为成熟血细胞的方法
AU2017367730A1 (en) 2016-12-02 2019-06-06 Taiga Biotechnologies, Inc. Nanoparticle formulations
AU2017379367B2 (en) 2016-12-20 2023-12-07 Sangui Bio Pty. Ltd Blood profiling with protease inhibitors
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
SG11201906933SA (en) * 2017-02-17 2019-09-27 Rubius Therapeutics Inc Functionalized erythroid cells
JP2020099202A (ja) * 2017-04-12 2020-07-02 Ａｇｃ株式会社 分化細胞スフェロイドの製造方法
CN107254437A (zh) * 2017-08-08 2017-10-17 安徽惠恩生物科技股份有限公司 一种人工诱导多能干细胞分化为红细胞的方法
JP2021509812A (ja) * 2018-01-05 2021-04-08 プレートレット バイオジェネシス， インコーポレイテッド 巨核球を産生するための組成物および方法
WO2020006539A1 (en) 2018-06-29 2020-01-02 Platelet Biogenesis, Inc. Compositions for drug delivery and methods of use thereof
GB201818045D0 (en) * 2018-11-05 2018-12-19 Nhs Blood & Transplant Method for producing erythroid cells
US12258583B2 (en) 2018-12-20 2025-03-25 Sumitomo Chemical Company, Limited Embryonic erythroblast-containing cell population and method for producing same, cell culture composition, and compound test method
CN110093314B (zh) * 2019-02-28 2021-06-15 中国人民解放军军事科学院军事医学研究院 红细胞脱核培养基及试剂盒
EP3947649A4 (en) * 2019-03-28 2022-12-14 The Hospital For Sick Children Method of generating hemangioblasts
AU2020272664A1 (en) 2019-04-08 2021-11-04 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
TW202106315A (zh) * 2019-04-26 2021-02-16 美商盧比亞斯治療公司 包括去核類紅血球之組成物
AU2020274117A1 (en) 2019-05-14 2021-12-02 Taiga Biotechnologies, Inc. Compositions and methods for treating T cell exhaustion
US20210147802A1 (en) * 2019-11-04 2021-05-20 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells using taurine or hypotaurine
US20210130780A1 (en) * 2019-11-04 2021-05-06 Rubius Therapeutics, Inc. Methods of generating enucleated erythroid cells using myo-inositol
GB201918586D0 (en) * 2019-12-17 2020-01-29 Patterson James Engineered platelets for targeted delivery of a therapeutic agent
CN116194573A (zh) * 2020-05-13 2023-05-30 长圣国际生技股份有限公司 生产类红血球及/或红血球之方法
EP4599051A2 (en) * 2022-10-05 2025-08-13 Garuda Therapeutics, Inc. Erythroid lineages derived from pluripotent cells
CN116426472A (zh) * 2023-06-08 2023-07-14 呈诺再生医学科技(北京)有限公司 一种促进造血干细胞或造血祖细胞分化为红细胞的诱导分化体系及其应用
CN116836920B (zh) * 2023-08-21 2024-05-24 广东横琴粤澳深度合作区齐美国际干细胞医院有限公司 一种无血清培养基及其制备间充质干细胞的方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5128259A (en) * 1989-10-27 1992-07-07 Hahnemann University Factor-dependent hematopoietic cell line exhibiting epo-induced erythrocyte maturation
CA2150471A1 (en) * 1992-12-11 1994-06-23 George Tidmarsh Megakaryocyte and platelet growth, production and composition
EP0802800B1 (en) 1993-08-12 2002-06-12 Neurotech S.A. Biocompatible immunoisolatory capsules containing genetically altered cells for the delivery of biologically active molecules
US5599705A (en) * 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
EP0739412B1 (en) 1993-12-23 2002-02-27 Infigen, Inc. ungulate EMBRYONIC STEM CELLS AS NUCLEAR DONORS AND NUCLEAR TRANSFER TECHNIQUES TO PRODUCE CHIMERIC AND TRANSGENIC ANIMALS
US5914268A (en) * 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5874301A (en) * 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US6063593A (en) 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
US6429012B1 (en) 1997-10-06 2002-08-06 Viacell, Inc. Cell population containing non-fetal hemangioblasts and method for producing same
US6361998B1 (en) 1998-06-25 2002-03-26 Hemosol Inc. Efficient culture of stem cells for the production of hemoglobin
EP1270719A3 (en) 1998-08-24 2003-06-25 Viacell, Inc. Cell population containing non-fetal hemangioblasts and method for producing same
EP1214443A4 (en) * 1999-09-07 2003-08-27 Advanced Cell Tech Inc RESTORATION OF THE TELOMER AND EXTENSION OF THE CELL LIFETIME IN CLONED ANIMALS FROM SENESCENT SOMATIC CELLS
CA2388497A1 (en) 1999-10-15 2001-04-26 Advanced Cell Technology, Inc. Method of producing differentiated progenitor cells by culturing morula or inner cell mass cells
AU2927501A (en) * 2000-01-07 2001-07-24 Oregon Health And Science University Clonal propagation of primate offspring by embryo splitting
US7795026B2 (en) * 2000-01-21 2010-09-14 The Johns Hopkins University School Of Medicine Methods for obtaining human embryoid body-derived cells
US6602711B1 (en) * 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
CA2401073A1 (en) * 2000-02-23 2001-08-30 Financial Engines, Inc. Load aware optimization
JP2004504834A (ja) 2000-08-01 2004-02-19 イスム　リサーチ　ディベロップメント　カンパニー 胚性細胞の定方向分化
US20030027330A1 (en) * 2001-04-02 2003-02-06 Robert Lanza Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells
EP1393066A4 (en) 2001-05-15 2006-01-25 Rappaport Family Inst For Res INSULIN-PRODUCING CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS
AU2002356896B2 (en) 2001-11-02 2007-11-01 Wisconsin Alumni Research Foundation Endothelial cells derived from primate embryonic stem cells
AU2002360424A1 (en) 2001-11-26 2003-06-10 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
CN1630716A (zh) 2001-12-07 2005-06-22 杰龙公司 人胚胎干细胞衍生的造血细胞
CA2473909A1 (en) 2002-01-15 2003-07-24 Advanced Cell Technology, Inc. Cloning b and t lymphocytes
US20040091936A1 (en) 2002-05-24 2004-05-13 Michael West Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank
EP1563058A4 (en) 2002-07-12 2005-12-28 Univ Singapore Haemangioblasts-Progenitor Cells
US20040052771A1 (en) 2002-07-12 2004-03-18 Lim Sai Kiang Hemangioblast progenitor cells
AU2002348947A1 (en) 2002-09-26 2004-04-19 Institut National De La Sante Et De La Recherche Medicale Compositions and methods for amplification of human stem cells
US7427603B2 (en) * 2002-09-26 2008-09-23 The Children's Medical Center Corporation Method of enhancing proliferation and/or hematopoietic differentiation of stem cells
US20040229350A1 (en) * 2003-05-12 2004-11-18 Nikolai Strelchenko Morula derived embryonic stem cells
US20070141703A1 (en) * 2003-11-19 2007-06-21 Stanley Edouard G Methods for producing blood products from pluripotent cells in cell culture
CN1302102C (zh) * 2003-12-29 2007-02-28 中国医学科学院血液学研究所 通过扩增巨核祖细胞和成熟巨核细胞制备巨核细胞制剂的方法及用途
CN1286970C (zh) * 2003-12-30 2006-11-29 上海伯瑞生物技术发展有限公司 由脐血cd34+细胞体外诱导生成巨核细胞的方法
US20050266556A1 (en) 2004-02-09 2005-12-01 Yoder Mervin C Isolation, expansion and use of clonogenic endothelial progenitor cells
EP1735429A4 (en) * 2004-03-31 2008-06-11 Newlink Genetics Corp METHOD AND COMPOSITIONS FOR OBTAINING EMBRYONAL STEM CELLS OF ABSTINENT HEMATOPOETIC STEM CELLS AND USES THEREOF
JP5139799B2 (ja) * 2004-06-04 2013-02-06 ユニベルシテ ピエール エ マリー キュリー（パリ シズエム） 赤血球細胞の生産方法
MX2007005200A (es) 2004-11-01 2007-05-11 Wisconsin Alumni Res Found Plaquetas a partir de celulas germinales.
US7893315B2 (en) * 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
JP4964121B2 (ja) 2005-02-23 2012-06-27 財団法人先端医療振興財団 血管内皮前駆細胞の生体外増幅方法
GB2440494B (en) 2005-06-01 2010-07-28 Wisconsin Alumni Res Found Method of forming dendritic from embryonic stem cells
JP2007089432A (ja) * 2005-09-27 2007-04-12 Reprocell Inc 幹細胞由来血小板産生増加法
EP1989296A2 (en) * 2006-02-09 2008-11-12 Wisconsin Alumni Research Foundation Erythroid cells producing adult-type -hemoglobin generated from human embryonic stem cells
CN101045915A (zh) 2006-03-29 2007-10-03 旭日干 一种卵母细胞生发泡移植技术
CN101045914A (zh) * 2006-03-29 2007-10-03 中国人民解放军军事医学科学院野战输血研究所 体外诱导造血干/祖细胞分化为成熟红细胞的方法与应用
AU2013201444B2 (en) 2006-04-14 2015-01-22 Astellas Institute For Regenerative Medicine Hemangio-colony forming cells
KR102230288B1 (ko) 2006-04-14 2021-03-22 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 콜로니 형성 세포
US20070298496A1 (en) * 2006-06-23 2007-12-27 Hung-Chih Kuo Method of deriving pluripotent stem cells from a single blastomere
WO2008067142A2 (en) * 2006-11-08 2008-06-05 Wisconsin Alumni Research Foundation In vitro differentiation of hematopoietic cells from primate embryonic stem cells
WO2008151386A1 (en) 2007-06-15 2008-12-18 Australian Stem Cell Centre Ltd Megakaryocyte differentiation
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
WO2009104825A1 (en) 2008-02-18 2009-08-27 Kaist Method for inducing the defferentiation of embryonic stem cells into hemangioblast
JP5198116B2 (ja) * 2008-03-28 2013-05-15 富士フイルム株式会社 インクジェットプリンタ、およびインクジェット記録方法
WO2009137629A2 (en) 2008-05-06 2009-11-12 Advanced Cell Technology, Inc. Methods for producing enucleated erythroid cells derived from pluripotent stem cells
CN102083963A (zh) 2008-05-06 2011-06-01 先进细胞技术公司 血管瘤集落形成细胞和非移植血管瘤细胞
HRP20181515T1 (hr) 2011-11-30 2018-11-16 Astellas Institute For Regenerative Medicine Mezenhimne stromalne stanice i upotreba povezana s njima
CN114558032B (zh) * 2012-12-21 2025-07-29 安斯泰来再生医药协会 由多能干细胞制备血小板的方法及其组合物
JP6459257B2 (ja) 2014-07-08 2019-01-30 富士ゼロックス株式会社 画像形成装置
CN106834224A (zh) * 2016-11-18 2017-06-13 西北农林科技大学 一种建立人多能干细胞诱导分化为成熟血细胞的方法
EP4081035A4 (en) * 2019-12-23 2024-03-27 Boston Medical Center Corporation HUMAN IPSC-BASED DERIVATION OF NK AND T CELLS BY EARLY NOTCH INDUCTION
CN116731967B (zh) * 2023-08-16 2023-11-17 南京大学 从多能干细胞通过诱导分化制备巨噬细胞的方法

Also Published As

Publication number Publication date
KR20110006705A (ko) 2011-01-20
JP2015061539A (ja) 2015-04-02
US9988602B2 (en) 2018-06-05
CN102083960B (zh) 2014-12-03
MX2010012089A (es) 2011-07-28
AU2009244236A1 (en) 2009-11-12
CN102083960A (zh) 2011-06-01
BRPI0912517A2 (pt) 2019-09-24
EP3282010A1 (en) 2018-02-14
KR101803562B1 (ko) 2017-12-01
EP2288690B1 (en) 2017-07-12
JP2011519577A (ja) 2011-07-14
KR20170102048A (ko) 2017-09-06
KR20210003301A (ko) 2021-01-11
CA3150872A1 (en) 2009-11-12
EP2288690A4 (en) 2012-02-29
JP2018027095A (ja) 2018-02-22
CN112280739A (zh) 2021-01-29
US20170121681A1 (en) 2017-05-04
AU2009244236B2 (en) 2015-03-12
JP5748654B2 (ja) 2015-07-15
WO2009137629A3 (en) 2010-01-21
CN104328087A (zh) 2015-02-04
US20200263132A1 (en) 2020-08-20
US20190002828A1 (en) 2019-01-03
EP2288690A2 (en) 2011-03-02
WO2009137629A2 (en) 2009-11-12
JP2020108397A (ja) 2020-07-16
US20110086424A1 (en) 2011-04-14
KR20190000928A (ko) 2019-01-03

Similar Documents

Publication Publication Date Title
US9988602B2 (en) Methods for producing enucleated erythroid cells derived from pluripotent stem cells
JP7138134B2 (ja) 血管コロニー形成細胞および非生着血管細胞
HK40004587A (en) Hemangio colony forming cells and non-engrafting hemangio cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140327

EEER Examination request

Effective date: 20140327

EEER Examination request

Effective date: 20140327

FZDE Discontinued

Effective date: 20231128